Efficacy and Safety of Riociguat in Incipient Pulmonary Vascular Disease as an Indicator for Early PAH
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled, multicenter, multinational study
investigating the effect of riociguat (MK-4836) in patients with early pulmonary vascular
disease.